Overview

A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

Status:
Enrolling by invitation
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Open-label, long-term extension study available to participants who have completed CNMAu8.201.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Clene Nanomedicine
Collaborator:
George Clinical